Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RGLS Regulus Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: RGLS
Price (delayed)
$8.2
Market cap
$567.72M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.72
Enterprise value
$519.6M
Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop
Highlights
RGLS's EPS has surged by 50% year-on-year and by 12% since the previous quarter
Regulus Therapeutics's quick ratio has increased by 47% from the previous quarter but it has decreased by 13% YoY
Regulus Therapeutics's net income has plunged by 52% YoY and by 2.5% from the previous quarter
Regulus Therapeutics's equity has decreased by 36% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of RGLS
Market
Valuations
Earnings
Shares outstanding
69.23M
Market cap
$567.72M
Enterprise value
$519.6M
Price to earnings (P/E)
N/A
Price to book (P/B)
7.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$51.75M
Net income
-$47.52M
EBIT
-$47.43M
EBITDA
-$47.08M
Free cash flow
-$43.66M
Per share
Balance sheet
Liquidity
EPS
-$0.72
EPS diluted
-$0.72
Free cash flow per share
-$0.66
Book value per share
$1.04
Revenue per share
$0
TBVPS
$1.13
Total assets
$74.83M
Total liabilities
$5.8M
Debt
$1.4M
Equity
$69.03M
Working capital
$67.3M
Debt to equity
0.02
Current ratio
16.31
Quick ratio
14.88
Net debt/EBITDA
1.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-53.3%
Return on equity
-57.5%
Return on invested capital
-92.9%
Return on capital employed
-67.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RGLS stock price
How has the Regulus Therapeutics stock price performed over time
Intraday
-0.12%
1 week
1.11%
1 month
3.14%
1 year
225.4%
YTD
418.99%
QTD
368.57%
Financial performance
How have Regulus Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.75M
Net income
-$47.52M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 59% year-on-year and by 3.4% since the previous quarter
Regulus Therapeutics's net income has plunged by 52% YoY and by 2.5% from the previous quarter
Price vs fundamentals
How does RGLS's price correlate with its fundamentals
Growth
What is Regulus Therapeutics's growth rate over time
Valuation
What is Regulus Therapeutics stock price valuation
P/E
N/A
P/B
7.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
RGLS's EPS has surged by 50% year-on-year and by 12% since the previous quarter
Regulus Therapeutics's equity has decreased by 36% YoY and by 10% from the previous quarter
Efficiency
How efficient is Regulus Therapeutics business performance
The ROIC has grown by 32% YoY but it has contracted by 32% from the previous quarter
Regulus Therapeutics's return on equity has decreased by 14% QoQ but it has increased by 12% YoY
RGLS's return on assets is down by 14% since the previous quarter but it is up by 3.8% year-on-year
Dividends
What is RGLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RGLS.
Financial health
How did Regulus Therapeutics financials performed over time
Regulus Therapeutics's current ratio has increased by 49% QoQ but it has decreased by 9% YoY
Regulus Therapeutics's quick ratio has increased by 47% from the previous quarter but it has decreased by 13% YoY
RGLS's debt is 98% smaller than its equity
The debt to equity has soared by 100% YoY
Regulus Therapeutics's equity has decreased by 36% YoY and by 10% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.